T-cell interactions vary between tumor microenvironments

by Melissa Rohman,Northwestern UniversityShown is a p-STAT3- non-reactive astrocyte (white arrow) in close proximity to a CD3+p-STAT3- T cell (blue arrow) and a CD163+p-STAT3- macrophage (red ar

Updated on: April 01,2024

T-cell interactions vary between tumor microenvironments

by Melissa Rohman,Northwestern UniversityShown is a p-STAT3- non-reactive astrocyte (white arrow) in close proximity to a CD3+p-STAT3- T cell (blue arrow) and a CD163+p-STAT3- macrophage (red ar

Updated on:April 01,2024

New report finds smoking rates, alcohol use, physical inactivity decreased during COVID-19

byAmerican Cancer SocietyNew ACS Report. Credit: American Cancer SocietyIn a new report, American Cancer Society (ACS) researchers discovered both favorable and unfavorable changes in major canc

Updated on: January 11,2024

New report finds smoking rates, alcohol use, physical inactivity decreased during COVID-19

byAmerican Cancer SocietyNew ACS Report. Credit: American Cancer SocietyIn a new report, American Cancer Society (ACS) researchers discovered both favorable and unfavorable changes in major canc

Updated on:January 11,2024

Researchers identify key metabolic regulators of drug resistance in the fight against pancreatic cancer

by Rebecca Brierley,University at BuffaloGraphical abstract. Credit:Molecular & Cellular Proteomics(2022). DOI: 10.1016/j.mcpro.2022.100409Researchers from the University at Buff

Updated on: February 20,2024

Researchers identify key metabolic regulators of drug resistance in the fight against pancreatic cancer

by Rebecca Brierley,University at BuffaloGraphical abstract. Credit:Molecular & Cellular Proteomics(2022). DOI: 10.1016/j.mcpro.2022.100409Researchers from the University at Buff

Updated on:February 20,2024

Peripheral surrogates of tumor burden to guide therapeutic strategies for HPV-associated malignancies

by Impact Journals LLCTumor intrinsic and extrinsic factors in the periphery that can serve as proxies of tumor burden. Credit:Oncotarget(2023). DOI: 10.18632/oncotarget.28487A new review

Updated on: January 22,2024

Peripheral surrogates of tumor burden to guide therapeutic strategies for HPV-associated malignancies

by Impact Journals LLCTumor intrinsic and extrinsic factors in the periphery that can serve as proxies of tumor burden. Credit:Oncotarget(2023). DOI: 10.18632/oncotarget.28487A new review

Updated on:January 22,2024

New treatment could be advance against cervical precancers

by Ernie MundellWomen who undergo regular Pap smears are no doubt familiar with the possibility of "precancerous" cells being detected.These cells—called cervical intraepithelial neoplasias

Updated on: April 28,2024

New treatment could be advance against cervical precancers

by Ernie MundellWomen who undergo regular Pap smears are no doubt familiar with the possibility of "precancerous" cells being detected.These cells—called cervical intraepithelial neoplasias

Updated on:April 28,2024

Shortage of vital children's cancer drug stirs fear and outrage

by Marie McCulloughCredit: CC0 Public DomainA critical shortage of a chemotherapy used to treat most childhood cancers has galvanized oncologists and parents of sick children.The U.S.medical com

Updated on: April 07,2024

Shortage of vital children's cancer drug stirs fear and outrage

by Marie McCulloughCredit: CC0 Public DomainA critical shortage of a chemotherapy used to treat most childhood cancers has galvanized oncologists and parents of sick children.The U.S.medical com

Updated on:April 07,2024

Potential therapeutic target for small cell lung cancer discovered

by Melissa Rohman,Northwestern UniversityGraphic model showing how POU2AF2 establishes the poised enhancer via SWI/SNF activity-dependent recruitment of the Polycomb complex in SCLC-P subtype ce

Updated on: April 28,2024

Potential therapeutic target for small cell lung cancer discovered

by Melissa Rohman,Northwestern UniversityGraphic model showing how POU2AF2 establishes the poised enhancer via SWI/SNF activity-dependent recruitment of the Polycomb complex in SCLC-P subtype ce

Updated on:April 28,2024

ASCO: Pembrolizumab superior for initial Tx of advanced NSCLC

(HealthDay)—For patients with programmed death ligand 1 (PD-L1)-expressing locally advanced or metastatic non-small-cell lung cancer (NSCLC), pembrolizumab is associated with better overall survival t

Updated on: March 30,2024

ASCO: Pembrolizumab superior for initial Tx of advanced NSCLC

(HealthDay)—For patients with programmed death ligand 1 (PD-L1)-expressing locally advanced or metastatic non-small-cell lung cancer (NSCLC), pembrolizumab is associated with better overall survival t

Updated on:March 30,2024

Researchers show potential liver cancer treatment by targeting cancer stem-like cells

by National University of SingaporeLiver cancer stem-like cells grown as tumourspheres that are sensitive to JAK/STAT small molecule inhibitors. Credit: National University of SingaporeLiver canc

Updated on: March 01,2024

Researchers show potential liver cancer treatment by targeting cancer stem-like cells

by National University of SingaporeLiver cancer stem-like cells grown as tumourspheres that are sensitive to JAK/STAT small molecule inhibitors. Credit: National University of SingaporeLiver canc

Updated on:March 01,2024

Depression linked to deadly inflammation in lung cancer patients

by Jeff Grabmeier,The Ohio State UniversityKaplan Meier survival curve for NSCLC patients stratified by NLR systemic inflammation, NLR < 5 and NLR ≥ 5 (n = 184), showing worse survival probab

Updated on: January 30,2024

Depression linked to deadly inflammation in lung cancer patients

by Jeff Grabmeier,The Ohio State UniversityKaplan Meier survival curve for NSCLC patients stratified by NLR systemic inflammation, NLR < 5 and NLR ≥ 5 (n = 184), showing worse survival probab

Updated on:January 30,2024

Study: Drugs reprogram genes in breast tumors to prevent endocrine resistance

by Sharita Forrest,University of Illinois at Urbana-ChampaignTargeting estrogen receptor-positive breast tumors with the XPO1 antagonist selinexor and the tamoxifen byproduct 4-OHT simultaneousl

Updated on: May 27,2024

Study: Drugs reprogram genes in breast tumors to prevent endocrine resistance

by Sharita Forrest,University of Illinois at Urbana-ChampaignTargeting estrogen receptor-positive breast tumors with the XPO1 antagonist selinexor and the tamoxifen byproduct 4-OHT simultaneousl

Updated on:May 27,2024

Revealing characteristics of circulating cell-free RNA in the blood of liver cancer patients

byScience China PressMOF materials efficiently enrich circulating nucleic acids (cfDNA and cfRNA) in blood through a simple operational process, enabling various downstream nucleic acid detectio

Updated on: March 30,2024

Revealing characteristics of circulating cell-free RNA in the blood of liver cancer patients

byScience China PressMOF materials efficiently enrich circulating nucleic acids (cfDNA and cfRNA) in blood through a simple operational process, enabling various downstream nucleic acid detectio

Updated on:March 30,2024